1. Home
  2. CCJ vs INSM Comparison

CCJ vs INSM Comparison

Compare CCJ & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cameco Corporation

CCJ

Cameco Corporation

HOLD

Current Price

$93.36

Market Cap

45.6B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$191.91

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCJ
INSM
Founded
1987
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.6B
41.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CCJ
INSM
Price
$93.36
$191.91
Analyst Decision
Buy
Strong Buy
Analyst Count
6
19
Target Price
$114.38
$178.71
AVG Volume (30 Days)
3.9M
2.7M
Earning Date
11-05-2025
10-30-2025
Dividend Yield
0.18%
N/A
EPS Growth
364.36
N/A
EPS
0.87
N/A
Revenue
$2,487,042,049.00
$447,022,000.00
Revenue This Year
$10.12
$43.10
Revenue Next Year
$6.89
$128.25
P/E Ratio
$108.09
N/A
Revenue Growth
23.88
30.34
52 Week Low
$35.00
$60.40
52 Week High
$110.16
$212.75

Technical Indicators

Market Signals
Indicator
CCJ
INSM
Relative Strength Index (RSI) 57.31 44.31
Support Level $86.40 $202.68
Resistance Level $93.88 $206.69
Average True Range (ATR) 3.90 6.67
MACD 0.86 -3.09
Stochastic Oscillator 92.83 0.91

Price Performance

Historical Comparison
CCJ
INSM

About CCJ Cameco Corporation

Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: